Platelet-Rich Plasma for Erectile Dysfunction
Trial Summary
What is the purpose of this trial?
There is great interest in restorative therapies (platelet-rich plasma (PRP) injections, shockwave therapy and stem cell therapy) for ED given their non-invasive nature. However, data is still limited and requires further research prior to widespread adoption. Unfortunately, therapies such as PRP injections are being widely used without clinical evidence demonstrating its safety or effectiveness for the treatment of erectile dysfunction. 2-7 To date, there are no treatments that address the underlying cause of endothelial dysfunction, although low-intensity shockwave therapy for ED has shown promising results. Platelet-derived therapies targeting inflammation and promoting tissue/nerve regeneration and may represent a potential treatment option towards this direction. The investigators propose to perform Canada's first pilot RCT to evaluate and safety and efficacy of PRP for the treatment of ED.
Research Team
Eligibility Criteria
This trial is for men experiencing erectile dysfunction. Participants should be seeking a non-invasive treatment option and have not found success with other therapies. Specific eligibility criteria are not provided, but typically include age range, health status, and the severity of ED.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Platelet-Rich-Plasma (Other)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Manitoba
Lead Sponsor
Charles Semba
University of Manitoba
Chief Medical Officer since 2020
MD from the University of Minnesota Medical School
Rick Pauls
University of Manitoba
Chief Executive Officer since 2010
Bachelor of Arts in Economics from the University of Manitoba, MBA in Finance from the University of North Dakota